Volume 13, Number 7—July 2007
Research
Virulence Characteristics of Klebsiella and Clinical Manifestations of K. pneumoniae Bloodstream Infections
Victor L. Yu*
, Dennis S. Hansen†, Wen Chien Ko‡, Asia Sagnimeni*, Keith P. Klugman§, Herman Goossens#, Marilyn M. Wagener*, Vicente J. Benedi**1, Meningeal Disease Surveillance in South Africa¶, and the International Klebsiella Study Group
, Dennis S. Hansen†, Wen Chien Ko‡, Asia Sagnimeni*, Keith P. Klugman§, Herman Goossens#, Marilyn M. Wagener*, Vicente J. Benedi**1, Meningeal Disease Surveillance in South Africa¶, and the International Klebsiella Study GroupTable 3
Underlying disease and virulence factors in community-acquired K. pneumoniae pneumonia*
| Country/condition | K1 or K2 serotype, % | Mucoid phenotype, % | Aerobactin production, % | Mouse mortality rate, %† |
|---|---|---|---|---|
| South Africa | 50 (12/24) | 75 (18/24) | 67 (16/24) | 58 |
| No underlying disease | 63 (12/19) | 89 (17/19) | 79 (15/19) | 78 |
| Underlying disease‡ | 0 (0/5) | 20 (1/5) | 20 (1/5) | 0 |
| Taiwan | 48 (11/43) | 65 (15/23) | 57 (13/23) | 35 |
| No underlying disease | 75 (9/12) | 100 (12/12) | 83 (10/12) | 50 |
| Underlying disease‡ | 18 (2/11) | 18 (2/11) | 27 (3/11) | 18 |
*Note that patients with no underlying disease were more likely to be infected by strains with the putative risk factors than were elderly patients or patients with serious underlying disease. See Results for p values.
†2 mice were tested for each available strain.
‡Underlying disease was defined as presence of end-stage liver or renal failure, metastatic malignancy, neutropenia, or age >70.
